GlassScriptPhysician profile
Kristin M Sobeck
NPI 1376904128
$6,055.59
in general payments reported to CMS, 2019-2025
37 companies · $868 in 2025
The $868 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,179 · 2022: $1,171 · 2023: $1,264 · 2024: $1,574 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,490 · Long Term Medical Supply Or Device Loan: $1,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.55 |
| Long Term Medical Supply Or Device Loan | $1,215.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,822.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $654.56 | 2021-2024 | Enhertu, Lynparza |
| Janssen Pharmaceuticals, INC | $285.14 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $283.16 | 2021-2024 | Krazati, Opdivo |
| Merck Sharp & Dohme LLC | $254.48 | 2021-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $216.80 | 2021-2025 | Enhertu, Injectafer, Vanflyta |
| Janssen Biotech, INC. | $180.13 | 2021-2025 | Tecvayli, Talvey |
| Glaxosmithkline, LLC. | $175.45 | 2021-2024 | Ojjaara, Zejula, Jemperli |
| Taiho Oncology, INC. | $124.44 | 2021 | |
| Pfizer INC. | $108.90 | 2021-2025 | |
| Incyte Corporation | $101.25 | 2021-2023 | Monjuvi |
| Celgene Corporation | $88.17 | 2023-2024 | Reblozyl |
| Ipsen Biopharmaceuticals, INC | $68.75 | 2023 | Tazverik |
| Astellas Pharma US INC | $57.92 | 2025 | Vyloy |
| Rigel Pharmaceuticals, INC. | $47.57 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cti Biopharma Corp. | $45.94 | 2022-2023 | Vonjo |
| Gilead Sciences, INC. | $41.91 | 2023-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $39.77 | 2022-2023 | Imbruvica |
| Stemline Therapeutics INC. | $39.31 | 2023 | Orserdu |
| Menarini Silicon Biosystems, INC. | $36.16 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.93 | 2024 | Fruzaqla |
| Genmab U.S., INC. | $29.36 | 2022 | |
| Seagen INC. | $27.41 | 2021 | |
| Tersera Therapeutics LLC | $27.02 | 2025 | Xermelo |
| Abbvie INC. | $26.61 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.37 | 2022 | |
| Springworks Therapeutics, INC. | $22.57 | 2024 | Ogsiveo |
| Immunocore Limited | $22.39 | 2025 | Kimmtrak |
| Eisai INC. | $21.61 | 2024 | |
| Blue Earth Diagnostics | $21.44 | 2022 | |
| Lilly USA, LLC | $20.17 | 2021 | |
| Amag Pharmaceuticals, INC. | $20.00 | 2021 | |
| Myriad Genetic Laboratories, INC. | $19.37 | 2023 | Myrisk |
| Pharmacosmos Therapeutics INC. | $19.23 | 2024 | Monoferric |
| Jazz Pharmaceuticals INC. | $18.48 | 2021 | |
| Puma Biotechnology, INC. | $16.22 | 2021 | |
| Blueprint Medicines Corporation | $13.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Sobeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.